Patents by Inventor Lianshan Zhang

Lianshan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINEDIONES AND THEIR USE
    Publication number: 20140031358
    Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.
    Type: Application
    Filed: March 12, 2012
    Publication date: January 30, 2014
    Applicant: Eternity Bioscience Inc.
    Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
  • GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY
    Publication number: 20130116172
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 9, 2013
    Applicant: MARCADIA BIOTECH, INC.
    Inventors: Richard D. Dimarchi, Lianshan Zhang
  • GLP-1 pegylated compounds
    Patent number: 8183340
    Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 22, 2012
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
  • Pegylated Insulin Lispro Compounds
    Publication number: 20110105392
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: June 9, 2009
    Publication date: May 5, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Brandon Lee Doyle, Ryan John Hansen, Shun Li, Shahriar Shirani, Lianshan Zhang
  • Selective VPAC2 receptor peptide agonists
    Patent number: 7897573
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20100048460
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: February 26, 2007
    Publication date: February 25, 2010
    Inventors: Lianshan Zhang, Jorge Alsina-Fernandez
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20100009916
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 14, 2010
    Inventors: BENGT KRISTER BOKVIST, LIANSHAN ZHANG, JORGE ALSINA-FERNANDEZ
  • PEGYLATED INSULIN LISPRO COMPOUNDS
    Publication number: 20090312236
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 17, 2009
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Brandon Doyle, Ryan John Hansen, Shun Li, Sean Shirani, Lianshan Zhang
  • Selective VPAC2 receptor peptide agonists
    Patent number: 7582608
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Glp-1 Pegylated Compounds
    Publication number: 20090215981
    Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.
    Type: Application
    Filed: May 11, 2006
    Publication date: August 27, 2009
    Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, JR., Andrew Mark Vick, Lianshan Zhang
  • Polyethylene glycol linked GLP-1 compounds
    Patent number: 7557183
    Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Richard Dennis DiMarchi, Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20090118167
    Abstract: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.
    Type: Application
    Filed: August 11, 2005
    Publication date: May 7, 2009
    Applicant: Eli Lilly and Company Patent Division
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20090082276
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: February 20, 2007
    Publication date: March 26, 2009
    Inventors: Lianshan Zhang, Jorge Alsina-Fernandez
  • Extended glucagon-like peptide-1 analogs
    Patent number: 7482321
    Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: January 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Wayne David Kohn, Rohn Lee Millican, Lianshan Zhang
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080318845
    Abstract: The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: December 25, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080234198
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: October 24, 2006
    Publication date: September 25, 2008
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Selective Apac2 Receptor Peptide Agonists
    Publication number: 20080194482
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 28, 2006
    Publication date: August 14, 2008
    Inventors: Jorge Alsina-Fernandez, Bengt Krister Bokvist, Lianshan Zhang
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080146500
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: June 19, 2008
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • Polyethylene Glycol Linked Glp-1 Compounds
    Publication number: 20080113905
    Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Application
    Filed: March 19, 2004
    Publication date: May 15, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Richard Dennis DiMarchi, Wolgang Glaesner, John Lee Millican Jr, Andrew Mark Vick, Lianshan Zhang
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20080096811
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: May 19, 2005
    Publication date: April 24, 2008
    Applicant: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Jesper Lindgren Gromada, Robert Chadwick Cummins, Wolfgang Glaesner, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez